CVS Health: Strong Quarter, But Breakup Raises Questions

CVS Health’s Q3/26 revenue rose 5.4% to $108.4B, adjusted EPS increased 30.7% to $2.09, and the company raised guidance, exceeding expectations. CVS plans to separate into two public companies—CVS Health, covering insurance, PBM and care, and CVS Pharmacy, covering retail and clinics—by H1 2028. The article characterizes CVS shares as deeply undervalued despite recent volatility and views them as a long-term buy.

Analysis

The split is a potential valuation catalyst, but not automatically a value-creation event. The key economic question is whether the insurance/PBM/care businesses and retail/clinics can operate independently without losing purchasing leverage, customer referrals, data sharing, or shared infrastructure. Separation could make segment economics easier to assess; it could also expose each company to costs and contracting risks currently absorbed across the group. Competitors may benefit if pharmacy, PBM, or care-provider relationships are disrupted, but that is a conditional thesis—not an established outcome.

Near term, the upbeat quarter and higher guidance may support sentiment, but consolidated EPS growth does not establish that each business is improving. Verify segment-level operating results, cash conversion, medical-cost trends, PBM client retention, and the split’s expected costs and debt allocation before underwriting a rerating. Over the next 1–3 months, guidance delivery and credible separation detail matter more than the announced target date. Over 6–18 months, execution, standalone capital structures, and post-separation commercial agreements become the central risks; H1 2028 leaves ample time for slippage or changed terms.

Contrarian view: a cleaner structure could narrow a conglomerate discount, but the market may be underpricing stranded costs and the possibility that vertical integration is more valuable operationally than it appears in a sum-of-parts analysis. No valuation, segment, or transaction-cost data here supports a high-conviction price target or immediate directional trade.

Key Decisions for Investors

• Treat CVS as a watchlist/hold rather than buying solely on the optimistic assessment. Revisit after segment-level results and management’s quantified separation plan clarify standalone earnings and cash flow.
• Potentially scale into a long position only if guidance is reaffirmed and cash conversion supports the earnings improvement; size conservatively until debt allocation, stranded costs, and separation expenses are disclosed.
• Monitor for a relative-value opportunity against UnitedHealth, Cigna, or Walgreens if CVS separation-related customer or supplier disruption becomes observable; do not position on disruption as a base case without evidence.
• Falsifiers: a guidance reduction, deterioration in segment operating trends or cash conversion, weaker PBM retention, materially higher-than-expected separation costs, or a delay/change in the separation plan. Reassess the thesis if any emerge.